Previous 10 | Next 10 |
Simulations Plus's total return overperformed the Dow average for my 64 month test period by 471.60%, which is fantastic. Simulations Plus three-year past CAGR of 19% is well above average and will give you great growth with the increasing need for testing new drugs faster than before...
Image source: The Motley Fool. Simulations Plus Inc (NASDAQ: SLP) Q2 2021 Earnings Call Apr 12, 2021 , 4:15 p.m. ET Operator Continue reading For further details see: Simulations Plus Inc (SLP) Q2 2021 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q2 2021 Earnings Conference Call April 12, 2021, 04:15 PM ET Company Participants Jeff Stanlis - Hayden IR Shawn O'Connor - CEO Will Frederick - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Francois Brisebois - Oppenheimer David Windley - Jefferies ...
The following slide deck was published by Simulations Plus, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Simulations Plus, Inc. 2021 Q2 - Results - Earnings Call Presentation
Simulations Plus ([[SLP]] +0.1%) has received initial experimental results from a collaborative research agreement it entered with a large pharmaceutical company to evaluate the impact of the generative chemistry technology contained in the new Artificial Intelligence-driven Drug De...
80% of preliminary molecules tested exhibit submicromolar activity and acceptable ADME properties Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has...
Conference call to be on Monday, April 12, 2021, at 4:15 p.m. ET Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the second quarter of fiscal year 2021, the period ended February 28, 2021, after the close of the financi...
The following slide deck was published by Simulations Plus, Inc. in conjunction with this event. For further details see: Simulations Plus (SLP) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
RENAsym SAB to Provide Insights and Guidance for Development of Kidney Injury Software Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Servi...
Speakers from Academia, Large Pharma Collaborations and Regulatory Agencies shared their real-world impact using modeling & simulation technology Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pha...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...